Rheumatology最新文献

{"title":"Correction to: Unveiling the dynamics of B lymphocytes in systemic lupus erythematosus patients treated with belimumab through longitudinal single-cell RNA sequencing.","authors":"","doi":"10.1093/rheumatology/keae694","DOIUrl":"10.1093/rheumatology/keae694","url":null,"abstract":"","PeriodicalId":21255,"journal":{"name":"Rheumatology","volume":" ","pages":"2302"},"PeriodicalIF":4.7,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142897052","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction to: Efficacy and safety of belimumab in patients with lupus nephritis: a real-world retrospective observational study.","authors":"","doi":"10.1093/rheumatology/keae127","DOIUrl":"10.1093/rheumatology/keae127","url":null,"abstract":"","PeriodicalId":21255,"journal":{"name":"Rheumatology","volume":" ","pages":"2300"},"PeriodicalIF":4.7,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140065814","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Do functionality, strength, vascularization, inflammatory and biopsychosocial status improve by biopsychosocial model-based exercise in SSc?","authors":"Orkun Tüfekçi, Edibe Ünal, Batuhan E Aktaş, Aziz A Tan, İrem Hartuç Çevik, Erdem Karabulut, Aslı Pınar, Feza Korkusuz, Mehmet R Onur, Sedat Kiraz, Ali Akdoğan","doi":"10.1093/rheumatology/keae365","DOIUrl":"10.1093/rheumatology/keae365","url":null,"abstract":"<p><strong>Objectives: </strong>This study aimed to investigation of the effects of the Cognitive Exercise Therapy Approach [Bilişsel Egzersiz Terapi Yaklaşımı (BETY)], a supervised biopsychosocial model-based exercise intervention, on functionality, muscle strength, vascularization, anti-inflammatory and biopsychosocial status in SSc patients.</p><p><strong>Methods: </strong>Thirty-seven SSc patients were included. Twenty of them were recruited into the study group (SG) undergoing BETY group exercise sessions three times a week for 3 months and seventeen were in the control group (CG) following a home exercise program. Assessment tools were the Modified Rodnan Skin Score (mRSS), Scleroderma HAQ (SHAQ), Modified Hand Mobility in Scleroderma (mHAMIS), Duruoz Hand Index (DHI), Six-Min Walk Test (6-MWT), skeletal muscle strength measurements using an isokinetic dynamometer (Biodex System 3 Pro), Shear Wave Elastography, ELISA kits (for tumour necrosis factor-alpha, Interleukin-6, IL-10, serum irisin level), BETY-Biopsychosocial Questionnaire (BETY-BQ), Hospital Anxiety and Depression Scale (HADS) and Short Form-36 (SF-36).</p><p><strong>Results: </strong>The SG demonstrated improvements in SHAQ, mHAMIS, 6-MWT, BETY-BQ, HADS and SF-36 values, excluding the DHI scores (P < 0.05). In contrast, CG showed worsening in SHAQ-general scleroderma symptoms and HADS scores compared with SG (P < 0.05). IL-10 and TNF-alpha increased in both groups, also various vascular parameters were significantly different changed in SG than CG (P < 0.05). Muscle strength values improved in the SG but decreased in the CG, however, this was statistically not significant (P > 0.05).</p><p><strong>Conclusion: </strong>BETY can be recommended as a non-pharmacological approach to the disease management of SSc patients.</p>","PeriodicalId":21255,"journal":{"name":"Rheumatology","volume":" ","pages":"1940-1948"},"PeriodicalIF":4.7,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11962873/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141634379","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Avacopan for anti-neutrophil cytoplasm antibodies-associated vasculitis: a multicentre real-world study.","authors":"Charlotte Gabilan, Julie Belliere, Olivier Moranne, Pierre Pfirmann, Maxime Samson, Vincent Delattre, Benjamin Thoreau, Victor Gueutin, Annabel Boyer, Amélie Leurs, Quentin Astouati, Charles Ronsin, Thomas Quemeneur, David Ribes, Alexandre Karras, Stanislas Faguer","doi":"10.1093/rheumatology/keae359","DOIUrl":"10.1093/rheumatology/keae359","url":null,"abstract":"<p><strong>Objectives: </strong>Avacopan, a selective C5aR1 inhibitor, recently emerged as a glucocorticoid (GCs) sparing agent in anti-neutrophil cytoplasm antibodies (ANCA)-associated vasculitis (AAV). We aim to evaluate the tolerance and efficacy of avacopan given outside randomized clinical trials or with severe kidney involvement.</p><p><strong>Methods: </strong>In this multicentre retrospective study, we reviewed the clinical charts of patients with AAV and contraindication to high dose of GCs who received avacopan 30 mg b.i.d plus standard-of-care regimen owing to the French early access program between 2020 and 2023. Efficacy and safety data were recorded using a standardized case report form.</p><p><strong>Results: </strong>Among the 31 patients (median age 72 years), 10 had a relapsing AAV, 20 had anti-myeloperoxidase antibodies and 30 had kidney vasculitis. Induction regimen included rituximab (n = 27), cyclophosphamide (n = 2) or both (n = 2). Five patients did not receive GCs. Despite rapid GCs tapering (which were withdrawn in 23 patients before month 3), 25 patients (81%) had a favourable outcome and no severe adverse event. The estimated glomerular filtration rate increased from 19 [15; 34] to 35 mL/min/1.73 m2 [23; 45] at month 12 (P < 0.05), independently of kidney biopsies findings. One patient developed refractory AAV and two had a relapse while receiving avacopan. At month 12, ANCA remained positive in 10/18 patients (55.5%). Two patients developed severe adverse events leading to a withdrawal of avacopan (hepatitis and age-related macular degeneration).</p><p><strong>Conclusions: </strong>The GCs' sparing effect of avacopan was confirmed, even in patients with severe kidney vasculitis, but further studies are required to identify the optimal dosing of GCs when avacopan is used.</p>","PeriodicalId":21255,"journal":{"name":"Rheumatology","volume":" ","pages":"2214-2219"},"PeriodicalIF":4.7,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141604074","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Protracted COVID-19 pneumonia in B-cell-depleted patients.","authors":"Orhan Efe, Gabriel Sauvage, James Chung, Anushya Jeyabalan, Ayman Al Jurdi, Harish S Seethapathy, Karen A Laliberte, John L Niles","doi":"10.1093/rheumatology/keae703","DOIUrl":"10.1093/rheumatology/keae703","url":null,"abstract":"","PeriodicalId":21255,"journal":{"name":"Rheumatology","volume":" ","pages":"2303-2305"},"PeriodicalIF":4.7,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11962908/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142877829","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Caffeine and endothelial function in systemic lupus erythematosus.","authors":"Henning Morawietz","doi":"10.1093/rheumatology/keae652","DOIUrl":"10.1093/rheumatology/keae652","url":null,"abstract":"","PeriodicalId":21255,"journal":{"name":"Rheumatology","volume":" ","pages":"1581-1582"},"PeriodicalIF":4.7,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142807907","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comment on: Association of ankylosing spondylitis with the risk of cancer: a meta-analysis of cohort studies.","authors":"Po-Huang Chen, Cho-Hao Lee, Hong-Jie Jhou","doi":"10.1093/rheumatology/keae410","DOIUrl":"10.1093/rheumatology/keae410","url":null,"abstract":"","PeriodicalId":21255,"journal":{"name":"Rheumatology","volume":" ","pages":"2323-2324"},"PeriodicalIF":4.7,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141898081","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Incidence of checkpoint inhibitor-associated inflammatory arthritis, immunomodulation and mortality in cancer patients on immunotherapy: a retrospective cohort study.","authors":"Anne R Bass, Fenglong Xie, Deanna Jannat-Khah, Nilasha Ghosh, Karmela K Chan, Ashish Saxena, Jeffrey R Curtis","doi":"10.1093/rheumatology/keae343","DOIUrl":"10.1093/rheumatology/keae343","url":null,"abstract":"<p><strong>Objectives: </strong>Immune checkpoint inhibitor (ICI)-associated inflammatory arthritis (ICI-IA) occurs in 4-6% of ICI-treated patients based on one observational study. We identified cases of ICI-IA using administrative claims to study its incidence and characteristics at the population level.</p><p><strong>Methods: </strong>We used the Medicare 5% sample to identify patients initiating ICIs. Cancer patients were identified by having ≥2 ICD-9/10-CM diagnosis codes from an oncologist for lung cancer, melanoma or renal/urothelial cancer. ICI-IA was defined as having two Medicare claims ≥30 days apart with combinations of ICD-9/10-CM diagnosis codes that favoured specificity. ICI-IA was identified in patients with a musculoskeletal diagnosis after ICI initiation, who had (i) no inflammatory arthritis or inflammatory rheumatic disease before ICI initiation ever, and (ii) no musculoskeletal complaint in the one year prior to ICI. We examined DMARD utilization and visits to rheumatology in patients with ICI-IA. Landmark analysis and a time varying Cox proportional hazards model for overall survival were constructed.</p><p><strong>Results: </strong>The incidence of ICI-IA was 7.2 (6.1-8.4) per 100 patient years. Patients with ICI-IA had a mean (s.d.) age of 73.5 (7.0) years, 48% were women and 91% were white. Median (IQR) time from ICI initiation to first ICI-IA diagnosis was 124 (56, 252) days. Only 24 (16%) received care from a rheumatologist, and 24 (16%) were prescribed a DMARD (46% by a rheumatologist). The HR for mortality in patients with ICI-IA was 0.86 (95% CI 0.59-1.26, P = 0.45).</p><p><strong>Conclusions: </strong>The incidence of ICI-IA identified in claims data is similar to that reported in observational studies; however, few patients are treated with a DMARD or are referred to rheumatologist. There was no difference in overall survival between ICI-treated patients with and without ICI-IA.</p>","PeriodicalId":21255,"journal":{"name":"Rheumatology","volume":" ","pages":"1637-1642"},"PeriodicalIF":4.7,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11962947/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141420676","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-term outcomes of childhood-onset systemic lupus erythematosus.","authors":"Anne Mirguet, Florence A Aeschlimann, Irene Lemelle, Roland Jaussaud, Paul Decker, Thomas Moulinet, Shirine Mohamed, Pierre Quartier, Michael Hofer, Olivia Boyer, Alexandre Belot, Aurélie Hummel, Nathalie Costedoat-Chalumeau, Brigitte Bader-Meunier","doi":"10.1093/rheumatology/keae344","DOIUrl":"10.1093/rheumatology/keae344","url":null,"abstract":"<p><strong>Objective: </strong>Data on the long-term outcome of patients with childhood-onset SLE (cSLE) are scarce. Aims of this study were to describe the long-term outcomes of cSLE and to identify factors associated with the development of damage and persistent disease activity.</p><p><strong>Methods: </strong>We conducted a retrospective multicentre study using data from the PEDIALUP registry of the Juvenile Inflammatory Rheumatism (JIR) cohort database. Demographic characteristics, clinical manifestations, laboratory, radiological, histological and treatment data were collected from medical records during follow-up.</p><p><strong>Results: </strong>A total of 138 patients with cSLE, diagnosed between 1971 and 2015, were included. With a median follow-up of 15.4 [9.6-22.4] years, 51% of patients had a SLICC-damage index (DI) score ≥1 at last follow-up with the musculoskeletal, cutaneous, renal, neurological and cardiovascular damage being the most common manifestations. The proportion of patients with a SLICC-DI score ≥1 increased significantly with the duration of the follow-up (P < 0.001). On multivariate analysis, duration of follow-up was associated with increased risk of cumulative damage (OR 1.08, 95% CI 1.01, 1.15, P = 0.035). At the last visit, 34% of patients still had active disease with a SLEDAI score of ≥6. On multivariate analysis, sub-Saharan African ethnicity was associated with 7-fold increased odds of having active disease at the last visit compared with Caucasians (OR 7.44, 95% CI 2.24, 24.74, P = 0.0002).</p><p><strong>Conclusion: </strong>The prevalence of damage remains high in patients with cSLE even when the diagnosis of cSLE has been made in the recent decades.</p>","PeriodicalId":21255,"journal":{"name":"Rheumatology","volume":" ","pages":"2209-2213"},"PeriodicalIF":4.7,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141620867","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Immunosuppressives discontinuation after renal response in lupus nephritis: predictors of flares, time to withdrawal and long-term outcomes.","authors":"Alexandros Panagiotopoulos, Eleni Kapsia, Ioannis El Michelakis, John Boletis, Smaragdi Marinaki, Petros P Sfikakis, Maria G Tektonidou","doi":"10.1093/rheumatology/keae381","DOIUrl":"10.1093/rheumatology/keae381","url":null,"abstract":"<p><strong>Objectives: </strong>The optimal duration of immunosuppressive (IS) treatment for lupus nephritis (LN) remains uncertain. We assessed the prevalence and predictors of IS tapering and discontinuation (D/C) in LN patients.</p><p><strong>Methods: </strong>Data from 137 inception cohort LN patients were analysed. We examined determinants of flares during tapering and after IS D/C, D/C achievement and time to D/C, and adverse long-term outcomes applying logistic and linear regression models.</p><p><strong>Results: </strong>IS tapering was attempted in 111 (81%) patients, and D/C was achieved in 67.5%. Longer time to achieve complete renal response (CR) [odds ratio (OR): 1.07, P = 0.046] and higher SLEDAI-2K at tapering initiation (OR: 2.57, P = 0.008) were correlated with higher risk of renal flares during tapering. Persistent hydroxychloroquine use (≥2/3 of follow-up) (OR: 0.28, P = 0.08) and lower SLEDAI-2K 12 months before IS D/C (OR: 1.70, P = 0.013) decreased the risk of post-D/C flares. Adverse outcomes (>30% estimated glomerular filtration rate decline, chronic kidney disease, end-stage renal disease, death) at the end of follow-up (median 124 months) were more frequent in patients with flares during IS tapering (53% vs 16%, P < 0.0038) but did not differ between IS D/C achievers and non-achievers. In proliferative LN, differences mirrored those in the entire cohort, except for time to D/C, which occurred 20 months earlier in membranous vs proliferative LN (β = -19.8, P = 0.014).</p><p><strong>Conclusion: </strong>Earlier CR achievement and lower SLEDAI-2K at tapering initiation prevent flares during IS tapering, while persistent hydroxychloroquine use and lower SLEDAI-2K 12 months before IS D/C prevent post-D/C flares. Flares during tapering increase the risk of unfavourable long-term outcomes. Earlier IS D/C is feasible in membranous LN.</p>","PeriodicalId":21255,"journal":{"name":"Rheumatology","volume":" ","pages":"1894-1903"},"PeriodicalIF":4.7,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11962912/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141749037","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}